Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase IB Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
A Phase III, Open-Label, Randomized Study of Sonrotoclax BGB-11417 Plus Zanubrutinib BGB-3111 Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Study Type: Treatment
Phase: III
NCTID: NCT06073821
Principal Investigator:
Marc Hoffmann
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin 7+3 vs Daunorubicin and Cytarabine Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and Daunorubicin and Cytarabine Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk Adverse Acute Myeloid Leukemia as Determined by MYELOMATCH; A MYELOMATCH CLINICAL TRIAL
A Randomized Phase II Study of Home Care Following Autologous Hematopoietic Stem Cell Transplantation
Study Type: Supportive Care
Phase: II
NCTID: NCT03667599
Principal Investigator:
Anthony Sung
A Phase 1 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
Study Type: Treatment
Phase: III
NCTID: NCT03007147
Principal Investigator:
Keith August
Randomized Phase II Study of daunorubicin and cytarabine liposome + Pomalidomide versus daunorubicin and cytarabine liposome in Newly Diagnosed AML with MDS-Related Changes.
Study Type: Treatment
Phase: II
NCTID: NCT04802161
Principal Investigator:
Jesus Gonzalez Lugo
A Phase I, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Acute Myeloid Leukemia
A Phase I/II Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma CLL/SLL or Non-Hodgkin Lymphoma NHL
Study Type: Treatment
Phase: I/II
NCTID: NCT03740529
Principal Investigator:
Marc Hoffmann
A Phase II Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway?Mutant Acute Lymphoblastic Leukemia
Study Type: Treatment
Phase: II
NCTID: NCT02723994
Principal Investigator:
Kevin Ginn